Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Christine, Furtek"'
Autor:
Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines, David Michelson
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Abstract Background Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development
Externí odkaz:
https://doaj.org/article/b7a42dd59c2848208857c8ea93bf3567
Autor:
Tiffini Voss, James Kost, Swati Pal Mercer, Christine Furtek, Christopher Randolph, Christopher Lines, Michael F. Egan, Jeffrey L. Cummings
Publikováno v:
Journal of Alzheimer's Disease. 92:341-348
Background: Delay of progression from prodromal Alzheimer’s disease (AD) to dementia is an important outcome in AD trials. Centralized adjudication is intended to improve the consistency of dementia diagnosis but has not been scrutinized. Objective
Autor:
Marissa F, Dockendorf, David, Jaworowicz, Rebecca, Humphrey, Melanie, Anderson, Sheila, Breidinger, Lei, Ma, Theresa, Taylor, Nicole, Dupre, Christopher, Jones, Christine, Furtek, Bhavna, Kantesaria, Kevin P, Bateman, Eric, Woolf, Michael F, Egan, Julie A, Stone
Publikováno v:
The AAPS Journal. 24
In-clinic venous dried blood spot (DBS) pharmacokinetic (PK) sampling was incorporated into two phase 3 studies of verubecestat for Alzheimer's disease (EPOCH [NCT01739348] and APECS [NCT01953601]), as a potential alternative to plasma PK sampling. I
Publikováno v:
The Journal of Clinical Psychiatry. 83
Background: The prevalence of treatment-resistant depression (TRD) among patients with pharmaceutically treated depression (PTD) varies greatly in publications. The aim of this study is to estimate the prevalence of TRD using 2 large claims databases
Autor:
Michael F. Egan, Saheeda Jackson, Cyrille Sur, Robert C. Sergott, James Kost, Christine Furtek, Annaswamy Raji, Amy Locco, Britta A. Mattson, Arpankumar Patel
Publikováno v:
Journal of Alzheimer's disease : JAD. 79(1)
Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thicknes
Autor:
David Michelson, Robert S. Stern, Christopher Randolph, Paul S. Aisen, Craig Shering, Nicole Dupre, Alette M. Wessels, Christopher Lines, James Kost, Bruno Vellas, Lyn Harper Mozley, Pierre N. Tariot, Tiffini Voss, Michael F. Egan, Christine Furtek, Yuki Mukai, John R. Sims, Jeffrey L. Cummings, Scott W. Andersen
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES. 16(11)
Introduction The APECS and AMARANTH trials showed that beta-secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on
Autor:
James Kost, Julie A. Stone, Bruno Vellas, Pierre N. Tariot, Paul S. Aisen, Erin Mahoney, David Michelson, Christine Furtek, Jeffrey L. Cummings, Yuki Mukai, Christopher Lines, Tiffini Voss, Michael F. Egan
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Alzheimer's Research and Therapy
Alzheimer's Research and Therapy, 2019, 11 (1), pp.68. ⟨10.1186/s13195-019-0520-1⟩
Alzheimer's Research and Therapy, BioMed Central, 2019, 11 (1), pp.68. ⟨10.1186/s13195-019-0520-1⟩
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Alzheimer's Research and Therapy
Alzheimer's Research and Therapy, 2019, 11 (1), pp.68. ⟨10.1186/s13195-019-0520-1⟩
Alzheimer's Research and Therapy, BioMed Central, 2019, 11 (1), pp.68. ⟨10.1186/s13195-019-0520-1⟩
Background Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1
Autor:
Yuki Mukai, Ming Xu, Julie A. Stone, Christine Furtek, Huub Jan Kleijn, Tiffini Voss, Michael F. Egan, James Kost, Nicole Dupre
Publikováno v:
Alzheimer's & Dementia. 15
Autor:
James Kost, David Scott, Christine Furtek, Cyrille Sur, Tiffini Voss, Michael F. Egan, Katarzyna Adamczuk, Talakad G. Lohith, Nicole Dupre, Theresa Taylor
Publikováno v:
Alzheimer's & Dementia. 15
Autor:
Cyrille Sur, Yuki Mukai, Michael F. Egan, Mercè Boada, Christine Furtek, David Michelson, Bruno Vellas, Tiffini Voss, Pierre N. Tariot, Ying Zhang, Lyn Harper Mozley, Yi Mo, Jeffrey L. Cummings, Paul S. Aisen, James Kost, Erin Mahoney, Wen Li, Christopher H. van Dyck
Publikováno v:
N Engl J Med
Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme